Monthly Archives: March 2015

‘Funding for infectious disease institutions’ paper published in JRSM Open

The latest publication to come out of the Research Investments in Global Health study is published today in JRSM Open. It covers the institutions that receive the funding and shows how for some disease areas, there are clear centres of excellence and some clear gaps in their portfolios.

The abstract is below, and see the full open access paper at the JRSM Open website.


Systematic analysis of funding awarded to inst
itutions in the United Kingdom for infectious disease research, 1997–2010

Objectives This study aimed to assess the research investments made to UK institutions for all infectious disease research and identify the direction of spend by institution.

Design Systematic analysis. Databases and websites were systematically searched for information on relevant studies funded for the period 1997–2010.

Setting UK institutions carrying out infectious disease research.

Participants None.

Main outcome measures Twenty academic institutions receiving greatest sum investments across infection are included here, also NHS sites, Sanger Institute, Health Protection Agency and the Medical Research Council. We measured total funding, median award size, disease areas and position of research along the R&D value chain.

Results Included institutions accounted for £2.1 billion across 5003 studies. Imperial College and University of Oxford received the most investment. Imperial College led the most studies. The Liverpool and London Schools of Tropical Medicine had highest median award size, whereas the NHS sites combined had many smaller studies. Sum NHS funding appears to be declining over time, whilst university income is relatively stable. Several institutions concentrate almost exclusively on pre-clinical research. In some areas, there is clearly a leading institution, e.g. Aberdeen and mycology research or UCL and antimicrobial resistance.

Conclusion UK institutions carry out research across a wide range of infectious disease areas. This analysis can identify centres of excellence and help inform future resource allocation for research priorities. Institutions can use this analysis for establishing expertise within their groups, identifying external collaborators and informing local research strategy.

Watch video of ResIn data presented at BSAC meeting

ResIn co-founder Michael Head recently presented data on antimicrobial resistance research funding at a British Society for Antimicrobial Chemotherapy meeting, taking place at the Wellcome Collection in London.

To see what Michael had to say, Click here to visit the website showing the talks presented at the meeting entitled ‘Re-stoking the therapy pipeline – How to stimulate the development of new antibiotics, diagnostics and novel therapies’.